Literature DB >> 8163579

N-acetylaspartate as an in vivo marker of neuronal viability in kainate-induced status epilepticus: 1H magnetic resonance spectroscopic imaging.

T Ebisu1, W D Rooney, S H Graham, M W Weiner, A A Maudsley.   

Abstract

N-acetylaspartate (NAA) has been proposed as a marker of neuronal density. Therefore, regional measurement of NAA by magnetic resonance spectroscopic imaging (MRSI) may provide a sensitive method for detection of selective neuronal loss, in contrast to conventional imaging techniques such as magnetic resonance imaging (MRI). To test this hypothesis, we produced selective neuronal injury by kainate-induced status epilepticus. Three days later three-dimensional 1H-MRSI was obtained and compared with conventional T2-weighted MRI and histological findings in normal and kainate-treated rats. Reduction of NAA determined by MRSI in piriform cortex, amygdala, and hippocampus correlated well with neuronal injury determined from histology. Changes of NAA, without any MRI changes in hippocampus, indicated greater sensitivity of MRSI for detection of neuronal injury. These results are consistent with the hypothesis that reduction of NAA measured by MRSI may be a sensitive marker of neuronal injury in vivo in a variety of disease states.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163579     DOI: 10.1038/jcbfm.1994.48

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  19 in total

1.  The effects of repeated endotoxin exposure on rat brain metabolites as measured by ex vivo 1HMRS.

Authors:  Sulie L Chang; Christine C Cloak; Lorenc Malellari; Linda Chang
Journal:  J Neuroimmunol       Date:  2005-09       Impact factor: 3.478

2.  Metabolic and pathological effects of temporal lobe epilepsy in rat brain detected by proton spectroscopy and imaging.

Authors:  T Tokumitsu; A Mancuso; P R Weinstein; M W Weiner; S Naruse; A A Maudsley
Journal:  Brain Res       Date:  1997-01-02       Impact factor: 3.252

3.  Effects of severe global ischemia on N-acetylaspartate and other metabolites in the rat brain.

Authors:  T Higuchi; S H Graham; E J Fernandez; W D Rooney; H L Gaspary; M W Weiner; A A Maudsley
Journal:  Magn Reson Med       Date:  1997-06       Impact factor: 4.668

4.  Hippocampal damage and affective disorders after treatment of cerebral aneurysms.

Authors:  Maria Wostrack; Benjamin Friedrich; Katrin Hammer; Kathrin Harmening; Anne Stankewitz; Florian Ringel; Ehab Shiban; Tobias Boeckh-Behrens; Sascha Prothmann; Claus Zimmer; Bernhard Meyer; Annette Förschler; Yu-Mi Ryang
Journal:  J Neurol       Date:  2014-08-14       Impact factor: 4.849

5.  Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease.

Authors:  T M Tsang; J N Haselden; E Holmes
Journal:  Neurochem Res       Date:  2009-01-16       Impact factor: 3.996

6.  In vivo glutamate decline associated with kainic acid-induced status epilepticus.

Authors:  Natalie M Zahr; Elena L Fasano Crawford; Oliver Hsu; Shara Vinco; Dirk Mayer; Torsten Rohlfing; Edith V Sullivan; Adolf Pfefferbaum
Journal:  Brain Res       Date:  2009-08-26       Impact factor: 3.252

7.  Reduced extrahippocampal NAA in mesial temporal lobe epilepsy.

Authors:  Susanne G Mueller; Joyce Suhy; Kenneth D Laxer; Derek L Flenniken; Jana Axelrad; Andres A Capizzano; Michael W Weiner
Journal:  Epilepsia       Date:  2002-10       Impact factor: 5.864

Review 8.  1H MR spectroscopy in patients with mesial temporal epilepsy.

Authors:  M Hájek; M Dezortová; V Komárek
Journal:  MAGMA       Date:  1998-12       Impact factor: 2.310

9.  Changes of metabolite profile in kainic acid induced hippocampal injury in rats measured by HRMAS NMR.

Authors:  Hui Mao; Donna Toufexis; Xiaoxia Wang; Agnès Lacreuse; Shaoxiong Wu
Journal:  Exp Brain Res       Date:  2007-08-01       Impact factor: 1.972

Review 10.  The neural bases of obsessive-compulsive disorder in children and adults.

Authors:  Tiago V Maia; Rebecca E Cooney; Bradley S Peterson
Journal:  Dev Psychopathol       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.